Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681521 | 0.85 | — | — | |
| SCHEMBL6512381 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL19546253 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL10829091 | 0.85 | ALOX15 (0.44) | ALOX15 | |
| SCHEMBL8775141 | 0.85 | — | — | |
| SCHEMBL384210 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL1673059 | 0.85 | ALOX15 (0.44) | ALOX15 | |
| SCHEMBL1046369 | 0.85 | DRD2 (0.52) | DRD2SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL15183069 | 0.83 | SIGMAR1 (0.37) | SIGMAR1ALOX15 | |
| SCHEMBL6659994 | 0.82 | DRD2 (0.50) | DRD2SIGMAR1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | DRD2 4873/4885SIGMAR1 3549/4885GNAI3 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.